Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease

被引:59
作者
Ueda, Seiji [1 ]
Yamagishi, Sho-Ichi
Kaida, Yusuke
Okuda, Seiya
机构
[1] Kurume Univ, Sch Med, Dept Med, Div Nephrol, Kurume, Fukuoka 8300011, Japan
[2] Kurume Univ, Sch Med, Div Cardiovasc Med, Kurume, Fukuoka 8300011, Japan
关键词
asymmetric dimethylarginine; CKD; CVD; dimethylarginine dimethylaminohydrolase; oxidative stress;
D O I
10.1111/j.1440-1797.2007.00840.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Decreased nitric oxide (NO) production and/or impaired NO bioavailability may occur in patients with chronic kidney disease (CKD), and could contribute to the elevation of blood pressure, cardiovascular disease (CVD) and the progression of renal injury in these patients. However, the underlying molecular mechanisms for reduced NO action in patients with CKD remains to be elucidated. Asymmetric dimethylarginine (ADMA) is a naturally occurring L-arginine analogue found in plasma and various types of tissues, acting as an endogenous NO synthase inhibitor in vivo. Further, plasma level of ADMA is elevated in patients with CKD and found to be a strong biomarker or predictor for future cardiovascular events. In addition, plasma level of ADMA could predict the progression of renal injury in these patients as well. These findings suggest that elevation of ADMA may be a missing link between CVD and CKD. In this review, we discuss the molecular mechanisms for the elevation of ADMA and its pathophysiological role for CVD in high-risk patients, especially focusing on patients with CKD.
引用
收藏
页码:582 / 590
页数:9
相关论文
共 121 条
  • [51] Direct, progressive association of cardiovascular risk factors with incident proteinuria - Results from the Korea Medical Insurance Corporation (KMIC) Study
    Jee, SH
    Boulware, LE
    Guallar, E
    Suh, I
    Appel, LJ
    Miller, ER
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (19) : 2299 - 2304
  • [52] REDUCED PLASMA L-ARGININE IN HYPERCHOLESTEROLEMIA
    JESERICH, M
    MUNZEL, T
    JUST, H
    DREXLER, H
    [J]. LANCET, 1992, 339 (8792) : 561 - 561
  • [53] Jiang JL, 2004, ACTA PHARMACOL SIN, V25, P893
  • [54] Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor
    Jin, JS
    DAlecy, LG
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 28 (03) : 439 - 446
  • [55] KAKIMOTO Y, 1970, J BIOL CHEM, V245, P5751
  • [56] Nitric oxide modulates vascular disease in the remnant kidney model
    Kang, DH
    Nakagawa, T
    Feng, L
    Johnson, RJ
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (01) : 239 - 248
  • [57] Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition
    Kielstein, JT
    Simmel, S
    Bode-Böger, SM
    Roth, HJ
    Schmidt-Gayk, H
    Haller, H
    Fliser, D
    [J]. KIDNEY & BLOOD PRESSURE RESEARCH, 2004, 27 (03) : 143 - 147
  • [58] Kielstein JT, 2002, J AM SOC NEPHROL, V13, P170, DOI 10.1681/ASN.V131170
  • [59] DETECTION OF N-G,N-G-DIMETHYLARGININE DIMETHYLAMINOHYDROLASE IN HUMAN TISSUES USING A MONOCLONAL-ANTIBODY
    KIMOTO, M
    WHITLEY, GS
    TSUJI, H
    OGAWA, T
    [J]. JOURNAL OF BIOCHEMISTRY, 1995, 117 (02) : 237 - 238
  • [60] Purification, cDNA cloning and expression of human NG,NG-dimethylarginine dimethylaminohydrolase
    Kimoto, M
    Miyatake, S
    Sasagawa, T
    Yamashita, H
    Okita, M
    Oka, T
    Ogawa, T
    Tsuji, H
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 258 (02): : 863 - 868